Search
Overview Recently Resected Patient Continuing Adjuvant Therapy Recurrence Post Adjuvant Therapy Metastatic Patient With Progression After GI/Surgeon Diagnosis About GIST
Home > GLIVEC and GIST > Recently Resected Patient
Print
Font size:

Recently Resected Patient

Recently Resected Patient/GLIVEC and KIT+ GIST
1,2
61 years old
3 months since diagnosis		 Gastric KIT+ GIST Original tumor: 3 cm
Mitotic rate: >5/50 HPFs		 16% RISK OF RECURRENCE3

Successfully resected patients may be convinced they are cancer free. They need to know:

  • GIST has malignant potential, even after resection1,4
  • GLIVEC is the only approved adjuvant therapy for KIT+ GIST5,6
  • The National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) recommend at least 12 months of imatinib therapy following resection in patients with significant risk of recurrence1,7*
  • Adjuvant therapy with GLIVEC can significantly lower the risk of tumor recurrence5,8

Make an informed decision regarding postsurgical treatment with GLIVEC

Risk of Recurrence

1 IN 2 PATIENTS EXPERIENCE RECURRENCE OF GIST FOLLOWING SURGERY 1 ,2

Rates of metastases or tumor-related death in GIST 3,a

MITOTIC RATE
(HPFs)		 TUMOR SIZE
(cm)		 GASTRIC
GIST		 JEJUNAL AND
ILEAL GIST		 DUODENAL GIST RECTAL
GIST
≤5/50 ≤2 0% 0% 0% 0%
>2 ≤5 1.9% 4.3% 8.3% 8.5%
>5 ≤10 3.6% 24% 34%b 57%b
>10 12% 52%
>5/50 ≤2 0%b 50%b N/Ac 54%
>2 ≤5 16% 73% 50% 52%
>5 ≤10 55% 85% 86%b 71%b
>10 86% 90%

a
Based on previously published long-term follow-up studies on 1055 gastric, 629 small intestinal, 144 duodenal, and 111 rectal GISTs.
b
Denotes tumor categories with very small numbers of cases. Some data combined, or missing, due to a small number of cases.
c
No tumors of such category were included in the study. Note that small intestinal and other intestinal GISTs show a markedly worse prognosis in many mitosis and size categories than gastric GISTs.
HPFs=high-power fields.
Adapted from Miettinen and Lasota, 2006.3
  • In accordance with current guidelines, mitotic rate, tumor site, and tumor size should be considered in risk assessments1,4
    • Tumors localized in the small intestine are more aggressive than gastric tumors of equal size and mitotic count3,5,6
  • Consider additional factors, including surgical margins and whether tumor rupture has occurred4
  • Depending on mitotic rate and anatomic location, a GIST of any size can have malignant potential3

Learn more about risk
of recurrence

FREE risk calculator!

Download this
interactive tool to your
desktop or iPhone

Test your RISK
AWARENESS with
this fun and
challenging activity!

References

  1. The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 2.2010). ©2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed August 28, 2010. To view the most recent and complete version of the guidelines, go online to www.nccn.org.
  2. Reichardt P, Blay J-Y, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther. 2010;10(2):221-232.
  3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.
  4. Casali PG, Blay J-Y; for the ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v98-v102.
  5. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol.2002;33(5):459-465.
  6. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(suppl 2):S1-S41.

Efficacy Data

LOWER THE RISK OF RECURRENCE FOLLOWING RESECTION OF PRIMARY
KIT+ GIST...
98% OF PATIENTS ON GLIVEC ACHIEVED RECURRENCE-FREE SURVIVAL AT 1 YEAR1

GLIVEC reduced the risk of recurrence by 88%1,*

GLIVEC significantly Improved Recurrence-Free Survival (RFS)1
GLIVEC significantly Improved Recurrence-Free Survival (RFS)

  • The trial examined tumor sizes ranging from 3 cm to ≥10 cm1
  • The significant difference was similar across all tumor size categories1

Help patients manage
common side effects
of GLIVEC

View Now

Learn more
about the pivotal
adjuvant trial


*Relative risk reduction.

Reference

  1. DeMatteo RP, Ballman KV, Antonescu CR, et al; for the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097-1104.

Risks and Benefits

ENABLE PATIENTS TO UNDERSTAND RECURRENCE RISK AND ADJUVANT TREATMENT BENEFITS

Adjuvant treatment post resection significantly improves clinical outcomes1,2

  • While on treatment, only 1 recurrence event was observed, compared with 41 events on placebo2
  • Discuss with patients their individual risk tolerance prior to making a treatment decision
    • An 8.5% risk of tumor recurrence may be acceptable for one patient but may be too high for another

The optimal treatment duration with GLIVEC in the adjuvant setting is unknown.1

Answer our survey question and receive immediate feedback!

See how Your colleagues around the world respond.

Question

null